new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)





Similar
Filing Names

Kyowa Hakko Kirin Co Ltd
Kyowa Hakko Kirin Co Ltd_20100114
Kyowa Hakko Kirin Co Ltd_20100121
  

Kyowa Hakko Kirin Co Ltd patents

Recent patent applications related to Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin Co Ltd is listed as an Agent/Assignee. Note: Kyowa Hakko Kirin Co Ltd may have other listings under different names/spellings. We're not affiliated with Kyowa Hakko Kirin Co Ltd, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "K" | Kyowa Hakko Kirin Co Ltd-related inventors




Date Kyowa Hakko Kirin Co Ltd patents (updated weekly) - BOOKMARK this page
04/13/17Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
04/13/17Acetyl-coa carboxylases
03/30/17Anti-tim-3 antibody
03/30/17Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
03/23/17Human monoclonal antibody human cd134 (ox40) and methods of making and using same
03/23/17Nucleic acid that inhibits expression of irf5
02/16/17Lipid nano particles comprising cationic lipid for drug delivery system
02/16/17Method for measuring toxicity of human csf
12/15/16Method for treatment of blood tumor using anti-tim-3 antibody
12/01/16Antibody composition-producing cell
11/17/16Nucleic acid capable of inhibiting expression of beta-2gpi
11/10/16Transgenic transchromosomal rodents for making human antibodies
10/20/16Cationic lipid
09/29/16Antibody to human il-3 receptor alpha chain
06/16/16Wnt signaling inhibitor
06/09/16Anti fgf23 antibody and a pharmaceutical composition comprising the same
04/21/16Recombinant antibody composition
03/17/16Antibody containing igg2 having amino acid mutation introduced therein
03/03/16Anti-folr1 antibody
02/11/16Novel antibody and antibody fragment introduced new modification sites
02/04/16Chemokine receptor antagonists and methods of use thereof
01/14/16Agent for preventing and/or treating ocular inflammatory disease
12/31/15Oligonucleotide
12/10/15Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
12/10/15Effective and efficient control of serum phosphate for optimal bone formation
12/03/15Cationic lipid
11/19/15Combinational compositions and methods for treatment of cancer
11/19/15Long non-coding rna used for anticancer therapy
11/05/15Pyridone compound
11/05/15Human cdr-grafted antibody and antibody fragment thereof
10/29/15Anti-cd98 antibody processes
10/22/15Nitrogen-containing heterocyclic compound
10/15/15Tricyclic compound
10/08/15Method for treatment of blood tumor using anti-tim-3 antibody
10/08/15Ring-fused heterocyclic compound
10/01/15Method for preventing reduction of polypeptide by adding amino acid to culture solution
10/01/15Method for preventing reduction of polypeptide by adding amino acid to culture solution
09/24/15Method for coating fine particles with lipid membrane
09/03/15Composition for suppressing expression of target gene
08/13/15Therapeutic agent for motor disorders
08/06/15Protein production method
07/09/15Method of stabilizing antibody and stabilized solution-type antibody preparation
07/02/154,6-hexadecadiene-2,4-dicarboxylic acid derivative
06/25/15Cationic lipid
06/11/15Dna encoding an anti-system asc amino acid transporter 2 (asct2) antibody
05/28/15Pharmaceutical composition comprising antibody composition which specifically binds to ccr4
05/21/15Stabilized human igg4 antibodies
05/14/15Quinazoline derivatives as kinase inhibitors
05/14/15Quinazoline derivatives as kinase inhibitors
04/30/15Sterol derivative
04/30/15Sterol derivative
04/23/15Antibody composition-producing cell
03/19/15Therapeutic agent for anxiety disorders
02/26/15Anti-cd40 antibody mutants
12/25/14Transgenic transchromosomal rodents for making human antibodies
12/18/14Chemokine receptor antagonists and methods of use thereof
11/13/14Stabilized human igg2 and igg3 antibodies
11/06/14Oligonucleotide
10/16/14Nitrogen-containing heterocyclic compounds
10/02/14Cationic lipid
09/04/14Anti-cd40 antibody mutants
09/04/14Methods of treating patients suffering from movement disorders
08/21/14Method of modulating the activity of functional immune molecules
08/07/14Chemokine receptor activity regulator
07/31/14Method for increasing deposition of complement c3b on bacterial surface and phagocytosis by phagocyte and a therapeutic method and a therapeutic agent for bacterial infections
Patent Packs
07/24/14Anti-folr1 antibody
07/17/14Protein comprising truncated form of extracellular region protein of frizzled2, and pharmaceutical composition for treating bone diseases which comprises said protein
07/03/14Human cdr-grafted antibody and antibody fragment thereof
07/03/14Compositions and methods for long acting molecules
07/03/14Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
06/19/14Pyrimidodiazepinone compound
06/12/14Dibenzooxepin derivative
05/29/14Method for purifying protein
05/15/14Method for treatment of blood tumor using anti-tim-3 antibody
05/15/14Method for inhibiting cell proliferation by oxidative stress
05/01/14Heterodimer protein composition
04/17/14Anti-cd40 antibody mutants
02/27/14Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
02/13/14Anti-tim-3 antibody
02/13/14Method of purifying protein
Patent Packs
02/13/14Human monoclonal antibody human cd134 (ox40) and methods of making and using same
02/13/14Lipid nano particles comprising combination of cationic lipid
02/06/14Anti-cd98 antibody processes
02/06/14Ring-fused heterocyclic derivative
02/06/14Lipid nano particles comprising cationic lipid for drug delivery system
12/19/13Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
12/05/13Anti system asc amino acid transporter 2 (asct2) antibody
12/05/13Highly concentrated anti-cd40 antibody pharmaceutical preparation
10/24/13Intrabuccally rapidly disintegrating tablet and a production the tablets
10/17/13Method for producing proteins
10/17/13Orally disintegrating tablet
10/10/13Thiazole derivatives
10/10/13Method for preparing aqueous solution containing culture medium and chelating agent
09/12/13Pharmaceutical composition
09/05/13Pharmaceutical composition for treating bone diseases which comprises protein comprising frizzled1, frizzled2 or frizzled7 extracellular cysteine-rich domain
08/29/13Nitrogen-containing aromatic heterocyclic derivative
08/29/13Granule and orally-disintegrating tablet containing drug causing bitterness
08/08/13Anti-system asc amino acid transporter 2 (asct2) antibody
07/25/13Antibody composition-producing cell
07/11/13Anti-cd4 antibody
05/23/13Method for producing substance
04/25/13Pyrazolopyrimidine derivative
04/18/13Anti-a(beta) oligomer humanized antibody
04/18/13Method for purifying protein using amino acid
03/14/13Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
03/07/13Anti-iga1 antibody
02/28/13Agonist antibody to human thrombopoietin receptor
12/27/12Anti-erbb3 antibody
12/27/12Ab1 kinase inhibitors
11/15/12Imidazole derivatives
Social Network Patent Pack
11/01/12Gene recombinant antibody and antibody fragment thereof
09/13/12Human artificial chromosome vector
09/13/12Method of treating an anxiety disorder
08/30/12Human artificial chromosome vector
08/02/12Pharmaceutical composition comprising aromatic heterocyclic compound
07/26/12Anti-tim-3 antibody
07/19/12Therapeutic agent for mood disorders
07/12/12Human cdr-grafted antibody and antibody fragment thereof
07/12/12Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
07/05/12Sterol derivative
Patent Packs
07/05/12Therapeutic agent for anxiety disorders
06/21/12Useful polypeptides
05/17/12Methods of treating patients suffering from movement disorders
05/10/12Compound inhibiting in vivo phosphorus transport and medicine containing the same
04/26/12Method for treatment of blood tumor using anti-tim-3 antibody
04/26/12Therapeutic agent for motor disorders
04/19/12Anti-cd27 humanized monoclonal antibody
04/12/12Antibody containing igg2 having amino acid mutation introduced therein
04/12/12Therapeutics for age-related macular degeneration
03/22/12Anti-il-3ra antibody for use in treatment of blood tumor
03/01/12Agonist antibody to human thrombopoietin receptor
02/16/12Anti system asc amino acid transporter 2 (asct2) antibody
01/26/12Method of depleting regulatory t cell
01/26/12Effector function enhanced recombinant antibody composition
01/26/12Methods of treating colorectal cancer
01/12/12Novel antibody and antibody fragment introduced new modification sites
01/12/12Anti-aß oligomer humanized antibody
01/12/12Anti-abeta oligomer humanized antibody
01/12/12Pharmaceutical composition
01/12/12Antibody variants composition
11/10/11Mitotic kinesin inhibitor
10/27/11Pharmaceutical composition comprising antibody composition which specifically binds to ccr4
10/13/11Antibody composition-producing cell
09/29/11Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
09/29/11Pharmaceutical composition for treating bone diseases which comprises protein comprising frizzled1, frizzled2 or frizzled7 extracellular cysteine-rich domain
09/22/11Transgenic animals and uses thereof
08/18/11Tricyclic compound
07/28/11Anti fgf23 antibody and a pharmaceutical composition comprising the same
07/28/11Therapeutic agent for migraine
06/23/11Method for modifying chromosomes
Patent Packs
06/16/11Interleukin 10 receptor (il-10r) antibodies and methods of use
06/02/11Nucleic acid capable of controlling degranulation of mast cell
05/12/11Industrially useful microorganism
05/12/11Therapeutic agent for cancer resistant to protease inhibitor
05/12/11Tetracyclic compound
05/05/11Inhibitor of analgesic tolerance
05/05/11Thiazole derivatives
03/31/11Stable multivalent antibody
03/17/11Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
03/10/11Antibody composition exhibiting cellular cytotoxicty due to glycosylation
03/10/11Human cdr-grafted antibody and antibody fragment thereof
03/03/11Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
03/03/11Antibody composition exhibiting cellular cytotoxicty due to glycosylation
02/24/11Protein production method
02/17/112-aminoquinazoline derivative
02/10/11Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
02/03/11Antibody composition exhibiting cellular cytotoxicty due to glycosylation
01/27/11Proliferation promoting agent for neural stem cells
01/27/11Novel nucleic acid
01/13/11Stable formulations of thiadiazole derivative
Social Network Patent Pack
01/13/11Recombinant antibody composition
12/09/10Anti-cd4 antibody
12/02/10Cell population with enhanced transplantation activity
12/02/10Nucleic acid capable of regulating the proliferation of cell
11/25/10Combinational compositions and methods for treatment of cancer
11/18/10Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
10/07/10Agent for prevention and/or treatment of skin diseases
10/07/10Thiazole derivatives
09/16/10Anti-cd40 monoclonal antibody
09/02/10Method for treating the th2-mediated disease
08/26/10Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
08/05/10Anti-system asc amino acid transporter 2 (asct2) antibody
07/29/10Pyrimidodiazepinone derivative
07/29/10Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient
07/22/10Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
07/08/10Anti-cd27 antibody
07/01/10Wrinkle-preventing and improving composition
06/24/10Recombinant protein s composition
06/17/10Method of depleting regulatory t cell
06/17/10Therapeutic and/or preventive agents for a sleep disorder
Social Network Patent Pack
06/17/10Imidazole derivatives
06/10/10Antibody composition-producing cell
06/03/10Gastrointestinal proliferative foctor and uses thereof
05/06/10Pharmaceutical composition comprising antibody composition which specifically binds to ganglioside gm2
05/06/10Method for producing antithrombin composition
04/29/10Pharmaceutical composition
04/22/10Pharmaceutical composition
04/22/10Novel nucleic acid
04/15/10Method of enhancing of binding activity of antibody composition to fcgamma receptor iiia
01/21/10Toll-like receptor 9 agonists
01/14/10Chimeric non-human animal
01/14/10Human artificial chromosome (hac) vector and human cell medicine comprising same
12/24/09Industrially useful microorganism
12/03/09Anti-a33 antibody
09/10/09Medicaments comprising gene recombinant antibody against ganglioside gd3
08/20/09Aurora inhibitors
08/13/09Anti-claudin-4 antibody
08/13/09Pentadienamide derivatives
07/30/09Glycoengineered, recombinant antibody
07/30/09Glycoengineered, recombinant antibody
01/21/10Toll-like receptor 9 agonists
01/14/10Human artificial chromosome (hac) vector and human cell medicine comprising same







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Kyowa Hakko Kirin Co Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kyowa Hakko Kirin Co Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';